Complete if Known	Unde	Pa	perwork Reduction Act of 1995, no	persons are required to re	spond to a collection of informa	ation unless it contains a valid OMB control
Sheet 01 of 02 Attorney Docket Number 2874-002 Sheet O1 O1 O2 Attorney Docket Number 2874-002	Sul Sul	bsginte f	or form 1449A/PTO			· · · · · · · · · · · · · · · · · · ·
Sheet 01 of 02 Attorney Docket Number 2874-002 Sheet O1 O1 O2 Attorney Docket Number 2874-002		₽	•		Application Number	09/911,904
Sheet 01 of 02 Attorney Docket Number 2874-002 Sheet O1 O1 O2 Attorney Docket Number 2874-002	DEMASH.	ĬFΩ	RMATION DISCL	OSURE	Filing Date	07/23/2001
Sheet O1 of O2 Attorney Docket Number 2874-002	C	TAT	EMENT RY ADD	LICANT	First Named Inventor	Spencer FARR, et al.
Sheet O1 of O2 Attorney Docket Number 2874-002	3	ייתו	FINE IN DIALI	LIVAG	Art Unit	1642
Sheet 01 of 02 Attorney Docket Number 2874-002 U. S. PATENT DOCUMENTS Examiner Initials' No.1 Document Number Number Number-Kind Code* (# Anormy) Number-Kind C					Examiner Name	Jeanine Anne Goldberg
U. S. PATENT DOCUMENTS Examiner Initials Cite No. Document Number Number-Kind Code ^{2 (# Intermy)} Publication Date MM-DD-YYYY Applicant of Cited Document Peges, Columns, Lines, Wh. Relevant Passages or Relev Figures Appear	Sheet	01	<u> </u>	1 00	Attorney Docket Number	·
Examiner Initials* O1 US- 5,654,401 US-						
No. No. No. No. No. Number-Kind Code ² (7 Innown) Number-Kin						
01 US- 5,654,401 08/05/1997 Clements et al. ———————————————————————————————————		T 2				Power Column Chan Wil
US-			Document Number	Publication Date	Name of Patentee	ment Relevant Passages or Rele
US- US- US- US-			Number-Kind Code ^{2 (F known)}	Publication Date	Name of Patentee	ment Relevant Passages or Rele
US- US- US-		No.1	Number-Kind Code ^{2 (7 known)}	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Docu	ment Relevant Passages or Rele
US- US-		No.1	Number-Kind Code ^{2 (7 known)} US- 5,654,401	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Docu	ment Relevant Passages or Rele
US-		No.1	Number-Kind Code ^{2 (7 known)} US- 5,654,401 US-	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Docu	ment Relevant Passages or Rele
		No.1	Number-Kind Code ^{t (# Incom)} US- 5,654,401 US- US-	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Docu	ment Relevant Passages or Rele
l us		No.1	Number-Kind Code ^{2 (F Incom)} US- 5,654,401 US- US- US-	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Docu	ment Relevant Passages or Rele
		No.1	Number-Kind Code ^{2 (F known)} US- 5,654,401 US- US- US- US-	Publication Date MM-DD-YYYY	Name of Patentes of Applicant of Cited Docu	ment Relevant Passages or Rele
		No.1	Number-Kind Code ^{† (F known)} US- 5,654,401 US- US- US- US- US- US-	Publication Date MM-DD-YYYY	Name of Patentes of Applicant of Cited Docu	ment Relevant Passages or Rele

US-US-US-US-US-US-US-US-

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code® Number® 'Rind Code® (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶	
CXY	02	WO 00/12760	03/09/2000	Incyte Pharmaceuticals, Inc.			
U	03	WO 99/05320	02/04/1999	Rapigene, Inc.			
	04	EP 0 292 879 A2	11/30/1988	Orion Corporation Ltd.			
V	05	WO 01/51667 A2	07/19/2001	Integriderm, L.L.C.			

••••••••••••				510 000 blue o c 2001 2070 1 0 001 1 0 0 0 0 0 0 0 0 0 0 0 0 0	
Examiner Signature	Q	. Godberg	Date Considered	IIII8/03	

*EXAMINER: Initial if referage considered, whether or not citation is in conformance with hirzy does not into the considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

N DATE: 07/07/2003 Express Mailing Label No. EV312365655US

02

PTO/SB/08b(05-03) Approved for use through 04/30/2003, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Office of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subtitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of 02

Complete if Known				
Application Number	09/911,904			
Filing Date	07/23/2001			
First Named Inventor	Spencer FARR, et al.			
Art Unit	1642			
Examiner Name	Jeanine Anne Goldberg			
Attorney Docket Number	2874-002			

		NON PATENT LITERATURE DOCUMENTS	<i>.</i>
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposlum, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Y	06	KRAEMER, et al., Regulation of Prostaglandin Endoperoxide H Synthase-2 Expression by 2,3,7,8-Tetrachlorodibenzo-p-dioxin, Archives of Biochemistry and Biophysics, 1996, 319-328, Volume 330, No. 2, Article No. 0259, Academic Press, Inc.	
7	07	BARTOSIEWICZ, et al., Development of a Toxicological Gene Array and Quantitative Assessment of This Technology, Archives of Blochemistry and Blophysics, 2000, 66-73, Volume 376, No. 1, Academic Press, Inc.	
	08	SCHRAML, et al., Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1999, 1966-1975, Volume 5, No. 8	
	09	FARR, et al., Concise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, 1999, 1-9, Volume 50, Society of Toxicology	
	10	MARTON, et al., Drug Target Validation and Identification of Secondary Drug Target Effects Using DNA Microarrays, Nature Medicine, 1998, 1293-1300, Volume 4, No. 11	
	11	SCHENA, et al., Parallel Human Genome Analysis: Microarry-based Expression Montoring of 1000 Genes, Proc. Natl. Acad. Sci. USA, 1996, 10614-10619, Volume 93	00 5000
J	12	Burczynski, et al., Toxicogenomics-Based Discrimination of Toxic Mechanism in HepG2 Human Hepatoma Cells, Toxicological Sciences, 2000, 399-415, Volume 58, Society of Toxicology	
)	*************		
;***;*********************************			

Examiner Signature 9. Holdberg Dat Con	te nsidered 11/18/03
--	-------------------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

considered. Include copy of this form with next communication to applicant,

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.